Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

Summit Therapeutics (SMMT) is a clinical-stage biopharmaceutical company focused on the development and marketing of medicinal therapies to treat oncology indications with serious unmet needs. In the past month, the company's stock has risen 57.1%. This upside came after management reported encouraging results from the phase III HARMONi-2 study, wherein treatment with ivonescimab bested Merck's (MRK) blockbuster oncology drug Keytruda in treating certain patients with non-small cell lung cancer (NSCLC). Per ...